ValTech Lifesciences

ValTech Lifesciences, founded in 2018 and based in Bern, Switzerland, is an early-stage innovator in the structural heart space. The company is developing a proprietary technology platform to enhance the design of heart valve prostheses, targeting key limitations of current devices such as thrombosis and durability. It operates as a B2B enabler, intending to license its patented designs to established valve prosthesis manufacturers. Currently in a pre-revenue, R&D-focused stage, the company is positioned to address a significant unmet need in the growing global heart valve market.

Proprietary heart valve design platform utilizing advanced fluid mechanics and engineering to create features that reduce thrombogenicity in mechanical valves and extend durability in biological valves.

ValTech competes indirectly with the massive R&D divisions of leading heart valve companies (Edwards, Medtronic, Abbott). Its direct competitors are other early-stage startups and academic spin-offs developing novel valve technologies (e.g., Foldax, PolyVascular). ValTech's differentiation lies in its specific focus on patented hemodynamic design features for existing valve paradigms rather than creating entirely new valve constructs.